# US 2016/0235837 A1 · THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235837 A1
- Document ID: US20160235837A1
- Status: Published application
- Kind: A1
- Application number: 15/029,169
- Filed: 2014-10-16
- Published: 2016-08-18
- Earliest claimed: 2013-10-16
- Inventors: Samuel BOGOCH; Elenore S. BOGOCH; Anne-Elenore Bogoch BORSANYI; Samuel Winston BOGOCH
- Web page: https://patentgrep.com/patent/US20160235837A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- G01N 33/56983: {Viruses}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides an isolated or synthesized protein fragment or peptide comprising at least one peptide sequence that is at least 50% homologous with at least one Replikin peptide sequence identified in a MERS CoV. The at least one peptide sequence may be at least 80% homologous with at least one Replikin peptide sequence identified in a MERS CoV. The at least one peptide sequence may be at least 46% homologous with at least one Replikin peptide sequence identified in a MERS CoV. The at least one peptide sequence may be at least 53% homologous with at least one Replikin peptide sequence.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

An immunogenic or blocking composition comprising at least one isolated or synthesized peptide that is at least 80% homologous with at least one of SEQ ID NO(s): 1-28.

### Claim at position 3

4-12. (canceled)

### Claim 13 (depends on 3)

The immunogenic or blocking composition of claim 3, wherein said at least one isolated or synthesized peptide consists of at least one of SEQ ID NO(s): 1-28.

### Claim 14 (depends on 3)

The immunogenic or blocking composition of claim 3, wherein said at least one isolated or synthesized peptide consists of at least one of SEQ ID NO(s): 1-9.

### Claim 15 (depends on 3)

The immunogenic or blocking composition of claim 3, wherein said at least one isolated or synthesized peptide consists of at least one of SEQ ID NO(s): 5, 18, 22, and 23.

### Claim 16 (depends on 3)

The immunogenic or blocking composition of claim 3, wherein said at least one isolated or synthesized peptide consists of at least one of SEQ ID NO(s): 6, 11, 12, 13, 14, 18, 19, 20, 26, 27, and 28.

### Claim 17

(canceled)

### Claim 18 (depends on 3)

The immunogenic or blocking composition of claim 3, wherein said at least one peptide comprises at least one Replikin sequence shared among at least one isolate of MERS CoV isolated from a human and at least one isolate of MERS CoV isolated from a camel.

### Claim at position 10

19-24. (canceled)

### Claim 25

An isolated or purified antibody, antibody fragment, or binding agent that specifically binds to at least a portion of a peptide that is at least 80% homologous with at least one of SEQ ID NO(s): 1-28.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

The isolated or purified antibody, antibody fragment, or binding agent of claim 25 that specifically binds to at least a portion of any one of SEQ ID NO(s): 1-28.

### Claim 28 (depends on 25)

The isolated or purified antibody, antibody fragment, or binding agent of claim 25 that specifically binds to at least a portion of any one of SEQ ID NO(s): 1-9.

### Claim 29

A method of making a vaccine comprising: isolating or synthesizing a peptide that is at least 80% homologous with at least one Replikin peptide sequence identified in a MERS CoV as a component of a vaccine; and making said vaccine.

### Claim 30

(canceled)

### Claim 31 (depends on 3)

The immunogenic or blocking composition of claim 3 comprising a mixture of at least nine peptides having different amino acid sequences, wherein said mixture comprises at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 1, at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 2, at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 3, at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 4, at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 5, at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 6, at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 7, at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 8, and at least one peptide having an amino acid sequence that is at least 80% homologous with SEQ ID NO: 9.

### Claim 32 (depends on 31)

The immunogenic or blocking composition of claim 31 comprising a mixture of at least one peptide of each of SEQ ID NO(s): 1-9.
